Aligos Therapeutics, Inc. — Form D

Aligos Therapeutics, Inc. of South San Francisco, CA, a company, filed a Form D exempt-offering notice with the SEC on 2020-01-16. The offering totals $125.0M, of which $85.0M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (35)

Showing 25 of 35 people.

NameRoleLocation
Kathleen GlaubDirectorSan Diego, CA
Peter HirthDirectorSouth San Francisco, CA
Peter MoldtDirectorSeattle, WA
Carole NeuchterleinDirectorSouth San Francisco, CA
Jack NielsenDirectorPalo Alto, CA
Tom WoiwodeDirectorDel Mar, CA
Michael YiDirectorSouth San Francisco, CA
Sushmita ChandaExecutive OfficerSouth San Francisco, CA
Brian DowdExecutive OfficerSouth San Francisco, CA
John FryExecutive OfficerLondon, X0
Lucinda QuanExecutive OfficerSouth San Francisco, CA
Julian SymonsExecutive OfficerSouth San Francisco, CA
Lesley Ann CalhounExecutive OfficerBoston, MA
Bridget Peter MartellDirectorSouth San Francisco, CA
Julian Peter SymonsExecutive OfficerSouth San Francisco, CA
Margarita Peter ChavezDirectorSouth San Francisco, CA
K. Peter HirthDirectorSouth San Francisco, CA
Heather Peter PrestonDirectorSouth San Francisco, CA
Lawrence M BlattDirectorSouth San Francisco, CA
Lawrence M BlattExecutive OfficerSouth San Francisco, CA
James Peter ScopaDirectorSouth San Francisco, CA
Hardean Peter AchneckExecutive OfficerSouth San Francisco, CA
Carole Peter NuechterleinDirectorSouth San Francisco, CA
Bridget Ann MartellDirectorSouth San Francisco, CA
Jack Ann NielsenDirectorSouth San Francisco, CA

Other filings by this issuer (2)

FiledFormOfferingSold
2025-02-28D$105.0M$105.0M
2023-11-07D$92.2M$92.2M

More